695213-59-3

Basic information

• Product Name: N-benzyl-1-pentyl-1H-indole-3-carboxaMide
• Synonyms: 1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide;1H-Indole-3-carboxaMide, 1-pentyl-N-(phenylMethyl)-;N-benzyl-1-pentyl-1H-indole-3-carboxaMide;SDB006 ada@tuskwei.com;bk-epdp;+008618031153937;SDB-006 ada@tuskwei.com whatsapp
• CAS NO: 695213-59-3
• Molecular Formula: C21H24N2O
• Molecular Weight: 320.42806
• EINECS: -0
• Product Categories: Food Additives;pharmaceutical intermediate
• Mol File: 695213-59-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-benzyl-1-pentyl-1H-indole-3-carboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-benzyl-1-pentyl-1H-indole-3-carboxaMide(695213-59-3)
• EPA Substance Registry System: N-benzyl-1-pentyl-1H-indole-3-carboxaMide(695213-59-3)

Safety Data

• Hazardous Substances Data: 695213-59-3(Hazardous Substances Data)

Usage

General Description

N-benzyl-1-pentyl-1H-indole-3-carboxamide is a synthetic chemical compound with the molecular formula C20H24N2O. It belongs to the class of indole-3-carboxamide compounds and is commonly used in research settings as a potential agonist for the cannabinoid receptor CB2. This chemical has been studied for its potential pharmacological properties, including its interaction with the endocannabinoid system and its possible role in the treatment of conditions such as inflammation, pain, and neurological disorders. Research on N-benzyl-1-pentyl-1H-indole-3-carboxamide continues to explore its potential therapeutic applications and biological effects.

Upstream product

• 1338925-23-7 1-pentyl-1H-indole-3-carbonyl chloride 
• 100-46-9 benzylamine 
• 727421-73-0 1-pentyl-1H-indole-3-carboxylic acid 
• 1430634-90-4 N-pentyl-3-trifluoroacetylindole 
• 110-53-2 1-Bromopentane 
• 59529-21-4 1-pentyl-1H-indole 
• 120-72-9 indole 

Relevant articles and documents

Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA

Synthetic cannabinoid receptor agonists (SCRAs) represent the most rapidly expanding class of new psychoactive substances (NPSs). Despite the prevalence and potency of recent chiral indole-3-carboxamide SCRAs, few pharmacological data are available regarding the enantiomeric bias of these NPSs toward human CB1 and CB2 receptors. A series of homochiral indole-3-carboxamides derived from (S)- and (R)-α-methylbenzylamine and featuring variation of the 1-alkyl substituent were prepared, pharmacologically evaluated, and compared to related achiral congeners derived from cumyl- and benzylamine. Competitive binding assays demonstrated that all analogues derived from either enantiomer of α-methylbenzylamine (14-17) showed affinities for CB1 (Ki = 47.9-813 nM) and CB2 (Ki = 47.9-347 nM) that were intermediate to that of the corresponding benzylic (10-13, CB1 Ki = 550 nM to >10 μM; CB2 Ki = 61.7 nM to >10 μM) and cumyl derivatives (6-9, CB1 Ki = 12.6-21.4 nM; CB2 Ki = 2.95-24.5 nM). In a fluorometric membrane potential assay, all α-methylbenzyl analogues (excluding 17) were potent, efficacious agonists of CB1 (EC50 = 32-464 nM; Emax = 89-104%) and low efficacy agonists of CB2 (EC50 = 54-500 nM; Emax = 52-77%), with comparable or greater potency than the benzyl analogues and much lower potency than the cumyl derivatives, consistent with binding trends. The relatively greater affinity and potency of (S)-14-17 compared to (R)-14-17 analogues at CB1 highlighted an enantiomeric bias for this series of SCRAs. Molecular dynamics simulations provided a conformational basis for the observed differences in agonist potency at CB1 pending benzylic substitution.